Baxter International (NYSE:BAX) recently announced weak fourth-quarter results and issued a disappointing guidance for fiscal year 2026. This performance led to a downgrade of the company's stock rating to 'hold'. Analysts point to persistent margin compression, significant debt risks, and a history of repeated earnings misses as key challenges. Despite what might appear as a cheap valuation, these factors make a near-term recovery for the stock highly improbable. Technical indicators further reinforce a prolonged downtrend, suggesting continued pressure on its share price.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis